Bambusa Therapeutics doses first volunteers in Phase I bispecific AD trial
Bambusa Therapeutics has announced the dosing of its first healthy volunteers as part of a Phase I trial on its …
Post
-
-
BullFrog AI partners with Eleison to enhance Phase III trial
BullFrog AI Holdings has announced a partnership agreement with Eleison Pharmaceuticals to apply its artificial intelligence (AI) solutions to Eleison’s …
-
Immune-Onc doses first subject in trial of IO-108 for HCC
Immune-Onc Therapeutics has dosed the first subject in the Phase Ib/II trial of IO-108 plus Roche’s atezolizumab and bevacizumab as …
-
Centralising genomic data crucial for recruitment in rare disease trials
Creating a centralised database for genomic test data will help the UK match up patients with rare disease trials, a …
-
Why pharma is still far from a treatment for galactosemia
Nearly three months after an experimental treatment for classic galactosemia was rejected by the US Food and Drug Administration (FDA), …
-
Astria commences Phase III hereditary angioedema therapy trial
Astria Therapeutics has commenced the randomised, placebo-controlled ALPHA-ORBIT Phase III trial of navenibart to treat individuals with hereditary angioedema (HAE). The …
-
NeOnc: bypassing the blood-brain barrier in brain cancer
Bypassing the blood-brain barrier (BBB) has been one of the greatest hurdles in the development of treatments for patients living …
-
New EU trial regulations could expedite approvals and address shortages
A major overhaul and consolidation of EU clinical trial regulations is paving the way to faster approvals, greater international coordination, …
-
Mandatory drug stock monitoring empowers EU to tackle shortages
Earlier this month, the newly empowered role of the European Union (EU)’s Executive Steering Group on Shortages and Safety of …
-
IAVI and Biofabri dose first adults and teens in TB vaccine trial
International non-profit research company IAVI has dosed the first patients in its Phase IIb trial of tuberculosis (TB) vaccine, which, …
-
Nektar completes enrolment in trial of rezpegaldesleukin for alopecia areata
Nektar Therapeutics has concluded target enrolment in the Phase IIb REZOLVE-AA trial of its investigational biologic therapy, rezpegaldesleukin, for treating …
-
Neuspera neuromodulation device hits “gold standard” in incontinence trial
Neuspera Medical’s percutaneous sacral neuromodulation (pSNM) has hit the “gold standard”, with 84.2% of patients suffering incontinence benefitting from a …
-
Imunon reports immunogenicity and safety data from DNA plasmid vaccine trial
Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN-101 DNA …
-
AstraZeneca reports positive outcomes from breast cancer combo therapy trial
AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of camizestrant plus …
-
Emalex eyes FDA approval for Tourette syndrome therapy after Phase III success
Emalex Biosciences is eyeing approval for its Tourette syndrome therapy after it achieved its primary and secondary endpoints in a …
